RADIOIMMUNOTHERAPY
Departments of Radiation Oncology and Nuclear Medicine
Stanford University School of Medicine
Radioimmunotherapy (RIT) is a promising new therapeutic modality for the
treatment of a wide variety of malignancies. RIT utilizes antibodies to
carry radioactivity to disease sites. Antibodies are immunoglobulin
molecules that bind to specific targeted antigens. Monoclonal antibodies
(MAB) are produced by a single clone of antibody producing cells, and are
highly specific for a given antigen. Radionuclides can be chemically linked
to MAB, resulting in stable radioimmunoconjugates for therapy. Two current
protocols are described.
CURRENT CLINICAL TRIALS
The following clinical studies are currently being conducted in the
Departments of Radiation Oncology and Nuclear Medicine at Stanford.
NON-HODGKIN'S LYMPHOMA
Stanford/Coulter Pharmaceutical: Randomized study to compare the activity and safety of 131-Iodine-radiolabeled Anti-B1 (anti-CD20) with unlabeled anti-B1 monoclonal antibody in chemotherapy refractory low grade non-Hodgkin's lymphoma. (STANFORD)
This is a randomized study designed to compare the efficacy and safety of radiolabeled anti-B1 (anti-CD20) with unlabeled anti-B1 as therapy for low grade B-cell lymphoma. There are two treatment arms - radiolabeled and unlabeled, with a unilateral crossover for patients initially treated with unlabeled antibody for therapy with the radiolabeled antibody at the time of disease progression.
[ See Expanded Protocol ]
Investigators: Dr. Susan J. Knox, Dr. Ron Levy, Dr. Michael L. Goris
Radiopharmacist: Dr. John French
Please contact: Jeannette Saal, R.N. at 650-725-1730.
NON-HODGKIN"S LYMPHOMA
Stanford/Coulter Pharmaceutical: Phase II Study of Iodine-131 Anti-B1 Antibody for Non-Hodgkin's Lymphoma Patients who have Previously Received Rituximab. (STANFORD)
This is a single-arm, open-label, multicenter study of Iodine-131 Anti-B1 Antibody for the treatment of Non-Hodgkin's lymphoma (NHL) patients who were previously treated with Rituximab antibody. Patients must have been treated with at least 4 doses of Rituximab and have progressed during or following Rituximab therapy.
{ See expanded Protocol }
Principal Investigator: Sandra Horning, M.D. - Division of Oncology
Other Investigators: Michael Goris, PhD, M.D. - Division of Nuclear Medicine
Susan Knox, PhD, M.D. - Department of Radiation Oncology
Medical Oncology Fellows: Jennifer Lucas, M.D. and Steve Horwitz, M.D.
Radiopharmacist: Dr. John French
Please contact: Jeannette Saal, R.N. - Research Nurse at 650-725-1730.
This is (STANFORD)
Webmaster: Jeannette Saal
jsaal@reyes.stanford.edu
Updated July 1, 1998
Jump to Radiation Oncology Home Page
Jump to Stanford University Home Page